Concord Biotech (CONCORDBIO)

FairStock Score: 95/100 — HIGH CONVICTION

Score breakdown: P/E: 0/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Zero debt with strong return on capital (ROCE 28.35%) and ROE 17.39%
• Piotroski F-score of 7/9 and Altman Z-score of 5.93 indicate solid financial health
• Promoter holding of 44.08% aligns management interests with shareholders
• Positive free cash flow of ₹85 Cr supports internal reinvestment
• Five-year revenue CAGR of 14.27% demonstrates past compounding ability

Concerns

• Expensive valuation: P/E of 40.20, P/B of 6.07, and EV/EBITDA of 25.19
• Recent profit decline of 3.98% with muted sales growth of 6.42%
• Negative margin of safety of -51.74% versus Graham Number of ₹804.38; DCF intrinsic value of ₹53.58 is far below the market price
• Low dividend yield of 0.88% provides little downside support

AI Analysis

Concord Biotech presents a paradox. On one hand, this is a pharmaceutical business with an excellent balance sheet: zero debt, return on capital employed of 28.35%, return on equity of 17.39%, and a Piotroski score of 7 out of 9. A Z-score of 5.93 tells me there's no financial distress. The five-year revenue CAGR of 14.27% shows a track record of compounding. Yet the latest numbers are less inspiring. Sales grew only 6.42%, while profits fell 3.98%. The latest quarter delivered ₹278 Cr in sales and ₹68 Cr in net profit. Free cash flow of ₹85 Cr is positive, but modest relative to the ₹12,769 Cr market cap. Now, valuation. At ₹1,051.10, the stock trades at 40.2 times earnings and 6.07 times book value. EV/EBITDA is 25.19. Graham would remind me that price is what you pay, value is what you get. The Graham Number is ₹804.38, giving a margin of safety of negative 51.74%. The DCF intrinsic value, at ₹53.58, is far below the market price. I don't anchor on any one model, but when every measure screams overvaluation, I listen. The dividend yield of 0.88% is barely a token. Promoter holding of 44.08% is reassuring, but it doesn't justify paying 40 times earnings for declining profits. This is a good company, but not a good investment at this price. I would wait for a much lower price or strong evidence of renewed growth before considering an entry. In investing, patience is a virtue.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer